One Gene Made Old Cells Act Younger — and Helped Mice Live Longer
Study: Plesa, Jung, and colleagues, “Transcriptomic reprogramming screen identifies SRSF1 as a regulator of aging,” Nature Aging, published October 14, 2026
Source: Read the original paper at Nature Aging
Team behind it: Wyss Institute at Harvard University, led by George Church, with collaborators at CIC bioGUNE in Spain
This brief is educational content, not medical advice. It explains one study; it does not recommend any treatment, supplement, or therapy.
The study in one paragraph
As we age, our cells don’t just wear out — the pattern of which genes are switched on and off drifts. Researchers built a computer model that could estimate a cell’s “age” from that gene-activity pattern, then used it as a scoreboard to test candidate genes, looking for one that could push old cells back toward a younger pattern. One gene stood out: SRSF1, a gene whose job is helping cells edit their RNA messages (a process called splicing). When the team dialed SRSF1 up in aged human skin cells in the lab, several hallmarks of aging eased. When they delivered it to aged mice, the mice aged more slowly by a standard frailty measure and lived longer.
What they did
- Built an aging “scoreboard.” They trained a machine-learning model on gene-expression data from human skin cells (fibroblasts) from donors of many ages, so it could predict a cell’s biological age from its gene activity.
- Screened candidate genes. They increased the activity of dozens of candidate genes in aged human cells and scored which ones moved the cells’ profiles toward “younger.” SRSF1 was the most consistent hit, confirmed across multiple donor cell lines.
- Tested it in mice. Using a harmless virus as a delivery truck, they carried the Srsf1 gene mainly into the livers of aged female mice, with a switch to turn the gene on later in life. They then tracked frailty and lifespan against a control group.
What they found
- In human cells (in dishes): More SRSF1 activity meant less cellular senescence (damaged cells that stop dividing but refuse to die), less proteostatic stress (trouble keeping proteins properly built and recycled), and less chronic low-grade inflammation (“inflammaging”). The cells looked younger by gene activity — and importantly, they kept their identity as skin cells rather than being reset into something else.
- In mice: Treated mice accumulated frailty about 44% more slowly, and sustained frailty was delayed by roughly 123 days.
- Lifespan: Median lifespan was 886 days in treated mice vs. 778 days in controls — about 14% longer.
What this means — in plain language
Most “rejuvenation” approaches try to rewind cells so aggressively that the cell can forget what it is — a real safety problem, because a cell that loses its identity is a step toward a tumor. This study is interesting because SRSF1 seemed to refresh the cells’ gene-activity patterns without erasing their identity, at least in these experiments. It also points at RNA splicing — how cells edit their own messages — as an underappreciated driver of aging, not just a side effect of it.
What it does NOT mean — the caveats, plainly stated
- This is a mouse study, not human evidence. The lifespan result comes from a small experiment: 10 treated mice and 9 control mice, all female. Mouse results in aging research often fail to translate to people. Nothing here shows SRSF1 extends human life.
- The cancer question must be flagged, not buried. In some other research contexts, too much SRSF1 activity has been linked to cancer. In this study, the researchers did not observe increased cancer risk — but a short, small mouse study cannot rule that out, and any future therapy built on this would need careful control and extensive safety testing. Treat the cancer link as an open, serious question.
- The delivery went mostly to the liver. Benefits elsewhere in the body were uneven — one DNA-methylation “aging clock” improved, others were less clear — so this is not evidence of whole-body rejuvenation.
- We don’t yet know how it works. The researchers themselves say the mechanism — exactly how SRSF1’s splicing changes produce these effects — is only beginning to be understood.
- There is nothing to buy or do. This is a gene-therapy research finding at the earliest stage. There is no supplement, drug, or clinic treatment based on it, and this brief recommends none.
The bottom line
A carefully designed screen found a single gene, SRSF1, that made aged human cells look measurably younger in the lab and helped a small group of aged mice stay less frail and live about 14% longer. It is a genuinely interesting lead — and it is years, possibly decades, from meaning anything for human health, with a real cancer-safety question to answer first. That’s exactly the kind of story this Journal exists to tell straight.